所有图片(1)

C2150000

胆钙化醇

European Pharmacopoeia (EP) Reference Standard

别名:
活化7-脱氢胆固醇, (+)-维生素 D3, 胆骨化醇, 活化7-脱氢胆甾醇
Empirical Formula (Hill Notation):
C27H44O
CAS号:
分子量:
384.64
Beilstein:
2339331
MDL编号:
PubChem化学物质编号:
NACRES:
NA.24

生物来源

synthetic

等级

pharmaceutical primary standard

agency

EP

形式

solid

manufacturer/tradename

EDQM

technique(s)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

mp

83-86 °C (lit.)

application(s)

pharmaceutical (small molecule)

格式

neat

储存温度

−20°C

SMILES string

CC(C)CCC[C@@H](C)[C@@]1([H])CC[C@@]([C@]1(C)CCC/2)([H])C2=C\C=C(C[C@@H](O)CC3)/C3=C

InChI

1S/C27H44O/c1-19(2)8-6-9-21(4)25-15-16-26-22(10-7-17-27(25,26)5)12-13-23-18-24(28)14-11-20(23)3/h12-13,19,21,24-26,28H,3,6-11,14-18H2,1-2,4-5H3/b22-12+,23-13-/t21-,24+,25-,26+,27-/m1/s1

InChI key

QYSXJUFSXHHAJI-YRZJJWOYSA-N

Gene Information

human ... VDR(7421)

正在寻找类似产品? Visit 产品对比指南

一般描述

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.
Cholecalciferol, also referred to as vitamin D3, promotes the absorption of calcium and phosphorus in the body to regulate bone growth. It is most commonly found in humans and animals and is produced in our skin when exposed to sunlight. It is used to treat and prevent bone disorders (such as rickets, osteomalacia).

应用

Cholecalciferol for system suitability may be used as an analytical reference standard for the determination of the analyte in pharmaceutical formulations by liquid chromatography.

生化/生理作用

维生素 D 借以发挥作用的受体是配体依赖性转录因子超家族的成员。调控正常细胞和癌细胞的增殖和分化。对乳腺癌、结肠癌和前列腺癌细胞具有抗增殖和抗转移作用。肠和骨骼中的活化维生素 D 受体维持着钙的吸收和平衡。

包装

Unit quantity: 1 mL. Subject to change. The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

注意

其他说明

Sales restrictions may apply.

象形图

Skull and crossbonesHealth hazard

警示用语:

Danger

危险分类

Acute Tox. 2 Dermal - Acute Tox. 2 Inhalation - Acute Tox. 2 Oral - STOT RE 1 Oral

储存分类代码

6.1A - Combustible, acute toxic Cat. 1 and 2 / very toxic hazardous materials

WGK

WGK 2

闪点(F)

Not applicable

闪点(C)

Not applicable

分析证书

原产地证书 (CofO)

更多文件

Cholecalciferol
European Pharmacopoeia Commission and European Directorate for the Quality of Medicines & Healthcare
European pharmacopoeia, 246(6), 2058-2059 (2013)
Sara S Oberhelman et al.
Mayo Clinic proceedings, 88(12), 1378-1387 (2013-12-03)
To determine whether a single monthly supplement is as effective as a daily maternal supplement in increasing breast milk vitamin D to achieve vitamin D sufficiency in their infants. Forty mothers with exclusively breast-fed infants were randomized to receive oral
Bich Tran et al.
The American journal of clinical nutrition, 99(1), 156-161 (2013-10-11)
Observational data suggested that supplementation with vitamin D could reduce risk of infection, but trial data are inconsistent. We aimed to examine the effect of oral vitamin D supplementation on antibiotic use. We conducted a post hoc analysis of data
Hongliu Ding et al.
Neurology, 81(17), 1531-1537 (2013-09-27)
To conclusively test for a specific association between the biological marker 25-hydroxy-vitamin D3, a transcriptionally active hormone produced in human skin and liver, and the prevalence and severity of Parkinson disease (PD). We used liquid chromatography/tandem mass spectrometry to establish
Cameron C Grant et al.
Pediatrics, 133(1), e143-e153 (2013-12-18)
To determine the vitamin D dose necessary to achieve serum 25-hydroxyvitamin D (25(OH)D) concentration ≥ 20 ng/mL during infancy. A randomized, double-blind, placebo-controlled trial in New Zealand. Pregnant mothers, from 27 weeks' gestation to birth, and then their infants, from

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门